These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 2797340)

  • 41. Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism.
    Akiba T; Marumo F; Owada A; Kurihara S; Inoue A; Chida Y; Ando R; Shinoda T; Ishida Y; Ohashi Y
    Am J Kidney Dis; 1998 Aug; 32(2):238-46. PubMed ID: 9708607
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Alterations in serum and urine parameters reflecting bone turnover in uremic patients during treatment with 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3.
    Mortensen BM; Gordeladze JO; Lyngdal PT; Aarseth HP; Gautvik KM
    Miner Electrolyte Metab; 1993; 19(2):78-85. PubMed ID: 8377728
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Improvement of severe secondary hyperparathyroidism in dialysis patients by intravenous 1 alpha(OH) vitamin D3, oral CaCO3 and low dialysate calcium.
    Moriniere P; el Esper N; Viron B; Judith D; Bourgeon B; Farquet C; Gheerbrant J; Chapuy M; Van Orshoven A; Pamphile R
    Kidney Int Suppl; 1993 Jun; 41():S121-4. PubMed ID: 8320904
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term effects of intermittent oral alphacalcidol, calcium carbonate and low-calcium dialysis (1.25 mmol L-1) on secondary hyperparathyroidism in patients on continuous ambulatory peritoneal dialysis.
    Brandi L; Nielsen PK; Bro S; Daugaard H; Olgaard K
    J Intern Med; 1998 Aug; 244(2):121-31. PubMed ID: 10095798
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum phosphate, parathyroid hormone and vitamin D metabolites in patients with chronic renal failure: effect of aluminum hydroxide administration.
    Takamoto S; Onishi T; Morimoto S; Imanaka S; Tsuchiya H; Seino Y; Yokokawa T; Iida N; Kumahara Y
    Nephron; 1985; 40(3):286-91. PubMed ID: 3839293
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of intermittent oral 1,25(OH)2D3 therapy on bone Gla protein in dialysis patients.
    Miki T; Nakatsuka K; Nishizawa Y; Emoto M; Morita A; Tabata T; Matsushita Y; Inoue T; Morii H
    Endocrinol Jpn; 1991 Oct; 38(5):479-83. PubMed ID: 1843267
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Vitamin D metabolites and bone mineralization in man.
    Bordier P; Rasmussen H; Marie P; Miravet L; Gueris J; Ryckwaert A
    J Clin Endocrinol Metab; 1978 Feb; 46(2):284-94. PubMed ID: 750606
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Long-term treatment of postmenopausal osteoporosis with active vitamin D3, 1-alpha-hydroxycholecalciferol (1 alpha-OHD3) and 1, 24 Dihydroxycholecalciferol (1, 24(OH)2D3).
    Shiraki M; Orimo H; Ito H; Akiguchi I; Nakao J; Takahashi R; Ishizuka S
    Endocrinol Jpn; 1985 Apr; 32(2):305-15. PubMed ID: 2995014
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effective suppression of parathyroid hormone by 1 alpha-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism.
    Tan AU; Levine BS; Mazess RB; Kyllo DM; Bishop CW; Knutson JC; Kleinman KS; Coburn JW
    Kidney Int; 1997 Jan; 51(1):317-23. PubMed ID: 8995749
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparisons between oral pulse alfacalcidol therapy and daily therapy in maintenance hemodialysis patients with secondary hyperparathyroidism: a randomized, controlled, and multicenter study.
    Gu Y; Ding F; Chen N; Mei CL; Qian JQ; Wang XY; Shi W; Hou FF; Li XW; Wang M; Chen YP
    Ren Fail; 2005; 27(2):205-12. PubMed ID: 15807187
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serum ionized calcium, as well as phosphorus and parathyroid hormone, is associated with the plasma 1,25-dihydroxyvitamin D3 concentration in normal postmenopausal women.
    Dawson-Hughes B; Harris S; Dallal GE
    J Bone Miner Res; 1991 May; 6(5):461-8. PubMed ID: 2068951
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Radioimmunoassay of carboxyl and amino terminal fragments of parathyroid hormone for the evaluation of secondary hyperparathyroidism in chronic renal failure.
    Zanella MT; Silva MC; Peres RB; Ferreira SR; Draibe SA; Vieira JG
    Braz J Med Biol Res; 1990; 23(3-4):235-43. PubMed ID: 2094538
    [TBL] [Abstract][Full Text] [Related]  

  • 53. 24,25-dihydroxy vitamin D3 treatment inhibits parathyroid-stimulated adenylate cyclase in iliac crest biopsies from uremic patients.
    Mortensen BM; Aarseth HP; Ganss R; Haug E; Gautvik KM; Gordeladze JO
    Bone; 1993; 14(2):125-31. PubMed ID: 8334029
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reduced binding of [3H]1,25-dihydroxyvitamin D3 in the parathyroid glands of patients with renal failure.
    Korkor AB
    N Engl J Med; 1987 Jun; 316(25):1573-7. PubMed ID: 3035373
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment with active vitamin D (alphacalcidol) in patients with mild primary hyperparathyroidism.
    Lind L; Wengle B; Sørensen OH; Wide L; Akerström G; Ljunghall S
    Acta Endocrinol (Copenh); 1989 Feb; 120(2):250-6. PubMed ID: 2644746
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Influence of sevelamer hydrochloride on serum concentration of whole (1-84) and N-terminally truncated (7-84) parathyroid hormone fragments in hemodialysis uremic patients.
    Chudek J; Piecha G; Kokot F; Wiecek A
    J Nephrol; 2003; 16(5):710-5. PubMed ID: 14733418
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lack of influence of recombinant human erythropoietin on parathyroid function in hemodialysis patients with secondary hyperparathyroidism.
    Lai YH; Tsai JC; Chen HC; Guh JY; Hwang SJ; Tsai JH
    Nephron; 1995; 70(2):223-8. PubMed ID: 7566308
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of refractory hyperparathyroidism in patients on hemodialysis by intermittent oral administration of 1,25(OH)2vitamin D3.
    Muramoto H; Haruki K; Yoshimura A; Mimo N; Oda K; Tofuku Y
    Nephron; 1991; 58(3):288-94. PubMed ID: 1896093
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of 22-oxacalcitriol on secondary hyperparathyroidism in hemodialysis patients.
    Doi S; Yorioka N; Usui K; Shigemoto K; Harada S
    Intern Med; 2003 Oct; 42(10):955-9. PubMed ID: 14606707
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.
    Lindberg JS; Moe SM; Goodman WG; Coburn JW; Sprague SM; Liu W; Blaisdell PW; Brenner RM; Turner SA; Martin KJ
    Kidney Int; 2003 Jan; 63(1):248-54. PubMed ID: 12472790
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.